Millions of individuals worldwide are afflicted with inflammatory diseases of the airways such as asthma that result in difficulty breathing, increased morbidity and mortality, making them significant health concerns. Currently, no cure exists for asthma, and it is one of the most expensive diseases to treat in developed countries. A hallmark of asthma is increased airway hyperreactivity and airway inflammation facilitated by specific innate and adaptive immune cells and their soluble mediators. While therapeutics targeting inflammatory soluble mediators in asthma are currently being used clinically, a more effective treatment may exist in the manipulation of immune cells to modulate their cytokine secretion during lung inflammation. Innate lymphoid cells (ILCs) have recently been identified as important cellular contributors in asthma. In non-allergic asthma, which affects approximately 40% of all asthmatics, type 3 ILCs (ILC3s) rapidly expand and secrete cytokines that contribute to both the initiation (interleukin (IL)-17) and potentiation (IL-22) of airway hyperreactivity and inflammation. We postulate that select aryl hydrocarbon receptor (AhR) ligands can be exploited to manipulate ILC3 cytokine secretion in airway inflammation, ultimately reducing it. Therefore, this application will test the hypothesis that different classes of AhR ligands differentially regulate receptor function to control ILC3 cytokine secretion, thereby modulating airway inflammation.
Our specific Aims will specifically address this hypothesis by: 1) determining the molecular mechanisms underlying the ability of AhR ligands to manipulate ILC3 cytokine secretion, and 2) investigating the therapeutic potential of AhR ligands and AhR-activated ILC3s to modulate airway inflammation. This research is highly innovative based on the potential for different classes of AhR ligands to differentially regulate AhR function and thus manipulate cytokine secretion by ILC3s during airway inflammation. Also, we propose novel approaches to study the mechanisms by which these selective AhR ligands alter the functionality of ILC3. Furthermore, we have assembled a highly experienced and collaborative team, with expertise in mucosal immunology, airway inflammation, and AhR biology. Therefore, the proposed studies are expected to lead to new therapeutic approaches to treat chronic airway inflammatory diseases, and significantly advance our understanding of how AhR signaling regulates respiratory immunity.

Public Health Relevance

Chronic inflammatory lung diseases such as asthma remain one of the greatest public health challenges of our time, affecting hundreds of million of individuals worldwide. This proposal suggests a novel approach, targeting the aryl hydrocarbon receptor AhR with selective ligands, such that certain receptor functions are either activated or repressed, thereby affecting the production of cytokines in type 3 innate lymphoid cells. This proposal will not only advance the field by increasing understanding of how activation of the AhR regulates respiratory immunity, but may also identify novel targets for the management of respiratory diseases, which would have a significant, positive effect on human health.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
1R15ES027648-01A1
Application #
9377287
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Humble, Michael C
Project Start
2017-08-15
Project End
2020-08-14
Budget Start
2017-08-15
Budget End
2020-08-14
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Montana
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
010379790
City
Missoula
State
MT
Country
United States
Zip Code
59812
Tait Wojno, Elia D; Beamer, Celine A (2018) Isolation and Identification of Innate Lymphoid Cells (ILCs) for Immunotoxicity Testing. Methods Mol Biol 1803:353-370